"You, B." - Selaus tekijän mukaan TUNICRIS-julkaisut

Viitteet 1-1 / 1

    • Olaparib plus bevacizumab first-line maintenance in ovarian cancer : final overall survival results from the PAOLA-1/ENGOT-ov25 trial 

      PAOLA-1/ENGOT-ov25 investigators; Ray-Coquard, I.; Leary, A.; Pignata, S.; Cropet, C.; González-Martín, A.; Marth, C.; Nagao, S.; Vergote, I.; Colombo, N.; Mäenpää, J.; Selle, F.; Sehouli, J.; Lorusso, D.; Guerra Alia, E. M.; Bogner, G.; Yoshida, H.; Lefeuvre-Plesse, C.; Buderath, P.; Mosconi, A. M.; Lortholary, A.; Burges, A.; Medioni, J.; El-Balat, A.; Rodrigues, M.; Park-Simon, T. W.; Dubot, C.; Denschlag, D.; You, B.; Pujade-Lauraine, E.; Harter, P. (08 / 2023)
      article
      Background: In the PAOLA-1/ENGOT-ov25 primary analysis, maintenance olaparib plus bevacizumab demonstrated a significant progression-free survival (PFS) benefit in newly diagnosed advanced ovarian cancer patients in clinical ...